Oric Pharmaceuticals (ORIC) logo

Oric Pharmaceuticals (ORIC) stock

Cancer therapies , market cap $800M

After-hours Fri
$7.37
+0.14%

Close $7.36 -4.42%

Why is ORIC down?

Down 45% in 3 months while the S&P 500 fell 10%.

  • It filed a prospectus for an at-the-market program for new shares of $200.0M on Feb 23, 2026.

Sources: Price history, Nov 20, 2026; Prospectus supplement, Feb 23, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ORIC moves

Free account, no card. An optional alert when ORIC moves or its score changes.Pro, $1 for a first month. An optional alert when ORIC moves or its score changes.Pro, 7 days free with a card. An optional alert when ORIC moves or its score changes.

Or see it live, free until Tuesday morning. No account.Or see one stock in full, free. No account.
1 more reason, free with an account →See every reason on ORIC →2 more reasons why ORIC is down, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-7
Poor
In its industry
#217of 273
Checks firing
0of 14
Trending down
From 52-week high
-49.9%
under its best in a year

ORIC's Quality Score fell 1 point on Fri, Nov 20, to -7. Its quiet day ended.

Follow ORIC's trial news. Pro members can get an alert when Oric Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ORIC files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next1H 2027“…Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027”Trial start · SEC filing · Nov 16
Cash$345M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “into 2H 2028”

Key facts on ORIC

Key facts on ORIC
Holding it backMoves 10.1% a day with no profit behind it
Latest filing8-K, Nov 16 Reported its quarterly results

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$345M, about 10 quarters (2.5 years) at the last year's spendingOn Sep 30 · the company says “into 2H 2028”

ORIC catalysts

Coming up

After its last 4 reports it closed +11.9% on average, higher 3 of 4 times.

4 past catalysts since 2023, with sizes and sources, for Pro members.

What's next for ORIC, and how long its cash lasts

Next step the company has named

1H 2027“Announced Redwood-1 global Phase 3 registrational trial in 1L EGFR atypical NSCLC, with initiation expected in 1H 2027”Trial start · SEC filing · Nov 16

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
Himalayas-1Phase 3 · Recruiting · 600 people · main data estimated Mar 2028 · NCT07723248

3 more trials, 1 with data due this year, 29 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 10 quarters

$345M in cash and investments (as the company counts them), at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2H 2028” (8-K, Nov 16).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3ASR, filed Mar 11, 2024)
  • At-the-market share sales program (424B5, filed Feb 23, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CFO Dominic Piscitelli sold 14,000 shares on Oct 20, under a planned sale. 8 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Jacob Chacko’s 7 filings and quotes.

Get an alert when ORIC files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How ORIC ranks in Biotech

ORIC is #217 of 273 by Quality Score.

How ORIC ranks in Biotech
RankStockQuality Score
217Oric Pharmaceuticals (ORIC) logoORICOric Pharmaceuticals-7

More in Biotech

When does ORIC report earnings, and what happens after?

Expected to report Mon Feb 22, after the close (in 93 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ORIC reported on Nov 16, 2026

The quarter

A loss of $0.44 a share, from $0.33.

“The increase was primarily due to an increase in external expenses related to the advancement of rinzimetostat, offset by lower enozertinib costs due to timing of manufacturing and clinical costs.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ORIC's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increases were primarily due to higher professional services costs.”

From its results filing (SEC filing · Nov 16)

1 more sentence, for Pro members.

The numbers

Market value
$800M
today
Free cash flow
-$129M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ORIC: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.6%+27.1%+6.4%
May 4Aug 3Nov 16
ReportedGapReaction5
days
Nov 16, 2026After close+2.5%+6.4%not yet
Aug 3, 2026After close+0.4%+27.1%+28.5%
May 4, 2026After close-2.3%-0.6%-6.7%

ORIC closed higher after 3 of its last 4 reports.

All 4 reports, and ORIC's Quality Score going into each

Nothing is firing on ORIC right now

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ORIC, and all 14 on every stock.Get in free →See the top 3 →Start Pro

ORIC RSI on Nov 20: 31.6, below its 50-day and 200-day averages

Not scored

RSI 31.6, MACD below signal, below both averages. Not scored.

The deep dive on ORIC

7 more findings on ORIC, each with its source, for Pro members.

ORIC share count over time

9% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of ORIC outstanding, as filed
Shares
outstanding
As
of
103.9MNov 9, 2026
103.7MJul 27, 2026
103.5MApr 27, 2026
100.4MFeb 12, 2026
Offerings, shelves, and splits of ORIC, from its filings
From its
filings
Filed
Set up an at-the-market program for up to $200M of shares, about 25% of its market valueFeb 23, 2026
Registered shares for a later sale (S-3)Jun 11, 2025
Registered shares for a later sale (S-3ASR)Mar 11, 2024
Registered shares for a later sale (S-3)Jan 26, 2024

ORIC's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold ORIC?

In ETFs: ORIC is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Oric Pharmaceuticals

ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.

119 employeesSouth San Francisco, CAoricpharma.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ORIC and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ORIC's score around: 7 things
  • 7 more filings explained, a plain line each
  • 3 more things pulling ORIC's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: ORIC's Quality Score is -7 (Poor), #217 of 273 in Biotech.

What does ORIC's Quality Score say?

ORIC scores -7 today, which Breakaway calls Poor. It is #217 of 273 in Biotech by Quality Score, with 0 of 14 chart checks firing. Down 45% in 3 months while the S&P 500 fell 10%. Cash lasts about 10 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ORIC's Quality Score?

ORIC scores -7 today, which Breakaway calls Poor (below zero). That is #217 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ORIC's -7.

When does ORIC report earnings?

Expected to report Mon Feb 22, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. ORIC closed higher after 3 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Oric Pharmaceuticals: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.